The immunological aspects of latency in tuberculosis

Clinical Immunology

Volumn 110, Issue 1, 2004, Pages 2-12

  Chan, John ^a   Flynn, JoAnne ^b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Immune response; Infection; Mycobacterium tuberculosis

Indexed keywords

CYTOKINE; INFLIXIMAB; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; REACTIVE NITROGEN SPECIES; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ANTIBODY;

ADULT; ANTIGEN PRESENTATION; CLINICAL FEATURE; DOWN REGULATION; FEMALE; HOST CELL; HOST PARASITE INTERACTION; HUMAN; IMMUNOLOGY; LATENT PERIOD; LUNG TUBERCULOSIS; MACROPHAGE; MALE; METABOLISM; MOLECULAR INTERACTION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PARASITE PREVALENCE; PHAGOSOME; PHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; TARGET CELL; TUBERCULOSIS; WEIGHT GAIN;

EID: 0842346271     PISSN: 15216616     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1521-6616(03)00210-9     Document Type: Short Survey

References (128)

1. Krause A.K. Tuberculosis the fifth cause of death in the United States. Am. Rev. Tuberc. 13:1926;183-191.
2. World Health Organization, WHO/TB/94.177, 1994.
3. Bloom B.R., Murray C.J. Tuberculosis: commentary on a reemergent killer. Science. 257:1992;1055-1064.
4. World Health Organization Press, TB deaths reach historic levels, March 21, 1996, 1-3.
5. Dye C., Scheele S., Dolin R., Pathania G., Raviglione M. Global burden of tuberculosis. Estimated incidence, prevalence, and mortality by country. JAMA. 282:1999;677-686.
6. Dolin P.J., Raviglione M.C., Kochi A. Global tuberculosis incidence and mortality during 1990-2000. Bull. WHO. 72:1994;213-220.
7. De Cock K.M., Chaisson R.E. Will DOTS do it? A reappraisal of tuberculosis control in countries with high rates of HIV infection. Int. J. Tuber. Lung Dis. 3:1999;457-465.
8. Mertens T.E., Low-Beer D. HIV and AIDS: where is the epidemic going? Bull. WHO. 74:1996;121-129.
9. Pablos-Mendez A., Raviglione M.C., Laszlo A., Binkin N., Rieder H.L., Bustreo F., Cohn D.L., Lambregts-van Weezenbeek C.S., Kim S.J., Chaulet P., Nunn P. Global surveillance for antituberculosis-drug resistance, 1994-1997. World Health Organization-International Union Against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. N. Engl. J. Med. 338:1998;1641-1649.
10. Snider D.E. Jr., Castro K.G. The global threat of drug-resistant tuberculosis. N. Engl. J. Med. 338:1998;1689-1690.
11. Styblo K. Recent advances in epidemiological research in tuberculosis. Adv. Tuberc. Res. 20:1980;1-63.
12. Robertson H.E. The persistence of tuberculous infections. Am. J. Pathol. 24:1933;711-718.
13. Grzybowski S., Allen E.A. The challenge of tuberculosis in decline. A study based on the epidemiology of tuberculosis in Ontario, Canada. Am. Rev. Respir. Dis. 90:1964;707-720.
14. Stead W.W. Tuberculosis among elderly persons: an outbreak in a nursing home. Ann. Intern. Med. 94:1981;606-610.
15. Stead W.W., Lofgren J.P., Warren E., Thomas C. Tuberculosis as an endemic and nosocomial infection among the elderly in nursing homes. N. Engl. J. Med. 312:1985;1483-1487.
16. Stead W.W., To T. The significance of the tuberculin skin test in elderly persons. Ann. Intern. Med. 107:1987;837-842.
17. Stead W.W., Lofgren J.P. Does the risk of tuberculosis increase in old age? J. Infect. Dis. 147:1983;951-955.
18. McKinney J.D., Jacobs W.R. Jr., Bloom B.R. Persisting problems in tuberculosis. Krause R.M. Emerging Infections. 1998;51-146 Academic Press, San Diego, CA.
19. Parrish N.M., Dick J.D., Bishai W.R. Mechanisms of latency in Mycobacterium tuberculosis. Trends Microbiol. 6:1998;107-112.
20. Stead W.W. The pathogenesis of pulmonary tuberculosis among older persons. Am. Rev. Respir. Dis. 91:1965;811-820.
21. Stead W.W. Pathogenesis of a first episode of chronic pulmonarytuberculosis in man: Recrudescence of residuals of the primary infection orexogenous reinfection? Am. Rev. Respir. Dis. 95:1967;729-745.
22. Stead W.W. Pathogenesis of the sporadic case of tuberculosis. N. Engl. J. Med. 277:1967;1008-1012.
23. Selwyn P.A., Hartel D., Lewis V.A., Schoenbaum E.E., Vermund S.H., Klein R.S., Walker A.T., Friedland G.H. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N. Engl. J. Med. 320:1989;545-550.
24. Opie E.L., Aronson J.D. Tubercle bacilli in latent tuberculous lesions and in lung tissue without tuberculous lesions. Arch. Pathol. 4:1927;1-21.
25. Feldman W.H., Baggenstoss A.H. The residual infectivity of the primary complex of tuberculosis. Am. J. Pathol. 14:1983;473-490.
26. Rasmussen K.N. The apical localization of pulmonary tuberculosis. Acta Tuberc. Scand. 34:1957;245-259.
27. Balasubramanian V., Wiegeshaus E.H., Taylor B.T., Smith D.W. Pathogenesis of tuberculosis: pathway to apical localization. Tuber. Lung Dis. 75:1994;168-178.
28. Dannenberg A.M. Jr., Rook G.A.W. Pathogenesis of pulmonary tuberculosis: an interplay of tissue damaging and macrophage-activating immune responses-dual mechanisms that control bacillary multiplication. Bloom B.R. Tuberculosis: Pathogenesis, Control and Protection. 1994;459-484 ASM Press, Washington, DC.
29. Adams D.O. The granulomatous inflammatory response. Am. J. Pathol. 84:1976;164-191.
30. Epstein W.L. Granulomatous hypersensitivity. Prog. Allergy. 11:1967;36-88.
31. MacMicking J., Xie Q., Nathan C. Nitric oxide and macrophage function. Annu. Rev. Immunol. 15:1997;323-350.
32. Chan J., Flynn J. Nitric oxide in Mycobacterium tuberculosis infection. Fang F. Nitric Oxide and Infection. 1999;281-310 Plenum, New York.
33. Nathan C., Shiloh M.U. Reactive oxygen and nitrogen intermediates in the relationship between mammalian hosts and microbial pathogens. Proc. Natl. Acad. Sci. U. S. A. 97:2000;8841-8848.
34. Chan J., Xing Y., Magliozzo R.S., Bloom B.R. Killing of virulent Mycobacterium tuberculosis by reactive nitrogen intermediates produced by activated murine macrophages. J. Exp. Med. 175:1992;1111-1122.
35. Chan J., Tanaka K., Carroll D., Flynn J., Bloom B.R. Effects of nitric oxide synthase inhibitors on murine infection with M. tuberculosis. Infect. Immun. 63:1995;736-740.
36. MacMicking J.D., North R.J., La Course R., Mudgett J.S., Shah S.K., Nathan C.F. Identification of nitric oxide synthase as a protective locus against tuberculosis. Proc. Natl. Acad. Sci. U. S. A. 94:1997;5243-5248.
37. Scanga C.A., Mohan V.P., Tanaka K., Alland D., Flynn J.L., Chan J. The NOS2 locus confers protection in mice against aerogenic challenge of both clinical and laboratory strains of Mycobacterium tuberculosis. Infect. Immun. 69:2001;7711-7717.
38. Flynn J., Scanga C.A., Tanaka K., Chan J. Reactivation of latent murine tuberculosis by inhibition of inducible nitric oxide synthase. J. Immunol. 160:1998;1796-1803.
39. Scanga C.A., Mohan V.P., Yu K., Joseph H., Tanaka K., Chan J., Flynn J.L. Depletion of CD4+ T cells causes reactivation of murine latent tuberculosis despite continued expression of IFN-γ and NOS2. J. Exp. Med. 192:2000;347-358.
40. Ehrt S., Shiloh M.U., Ruan J., Choi M., Gunzburg S., Nathan C., Xie Q.-W., Riley L.W. A novel antioxidant gene from Mycobacterium tuberculosis. J. Exp. Med. 186:1997;1885-1896.
41. Ruan J., St. John G., Ehrt S., Riley L., Nathan C. noxR3, a novel gene from Mycobacterium tuberculosis, protects Salmonella typhimurium from nitrosative and oxidative stress. Infect. Immun. 67:1999;3276-3283.
42. Chen L., Xie Q.W., Nathan C. Alkyl hydroperoxide reductase subunit C (AhpC) protects bacterial and human cells against reactive nitrogen intermediates. Mol. Cell. 1:1998;795-805.
43. Bryk R., Griffin P., Nathan C. Peroxynitrite reductase activity of bacterial peroxiredoxins. Nature. 407:2000;211-215.
44. Beckman J.S., Koppenol W.H. Nitric oxide, superoxide and peroxynitrite: the good, the bad, and the ugly. Am. J. Physiol. 271:1996;C1424-C1437.
45. Yu K., Mitchell C., Xing Y., Magliozzo R.S., Bloom B.R., Chan J. Toxicity of nitrogen oxides and related oxidants on mycobacteria: M. tuberculosis is resistant to peroxynitrite anion. Tuber. Lung Dis. 79:1999;191-198.
46. St. John G., Brot N., Ruan J., Erdjument-Bromage H., Tempst P., Weissbach H., Nathan C. Peptide methionine sulfoxide reductase from Escherichia coli and Mycobacterium tuberculosis protects bacteria against oxidative damage from reactive nitrogen intermediates. Proc. Natl. Acad. Sci. U. S. A. 98:2001;9901-9906.
47. Bryk R., Lima C.D., Erdjument-Bromage H., Tempst P., Nathan C. Metabolic enzymes of mycobacteria linked to antioxidant defense by a thioredoxin-like protein. Science. 295:2002;1073-1077.
48. Ouellet H., Ouellet Y., Richard C., Labarre M., Wittenberg B., Wittenberg J., Guertin M. Truncated hemoglobin HbN protects Mycobacterium bovis from nitric oxide. Proc. Natl. Acad. Sci. U. S. A. 99:2002;5902-5970.
49. Mckinney J.D., Honer zu Bentrup K., Munoz-Elias E.J., Miczak A., Chen B., Chan W.-T., Swenson D., Sacchettini J.C., Jacobs W.R. Jr., Russell D.G. Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase. Nature. 406:2000;735-738.
50. Nathan C. Inducible nitric oxide synthase in the tuberculous human lung. Am. J. Respir. Crit. Care Med. 166:2002;130-131.
51. Nicholson S., Bonecini-Almeida M. da G., Lapa e Silva J.R., Nathan C., Xie Q., Mumford R., Weidner J.R., Calaycay J., Geng J., Boechat N., Linhares C., Rom W., Ho J.L. Inducible nitric oxide synthase in pulmonary alveolar macrophages from patients with tuberculosis. J. Exp. Med. 183:1996;2293-2302.
52. Nozaki Y., Hasegawa Y., Ichiyama S., Nakashima I., Shimokata K. Mechanism of nitric oxide-dependent killing of Mycobacterium bovis BCG in human alveolar macrophages. Infect. Immun. 65:1997;3644-3647.
53. Wang C.H., Liu C.Y., Lin H.C., Yu C.T., Chung K.F., Kuo H.P. Increased exhaled nitric oxide in active pulmonary tuberculosis due to inducible NO synthase upregulation in alveolar macrophages. Eur. Respir. J. 11:1998;809-815.
54. Choi H.-S., Rai P.R., Chu H.W., Cool C., Chan E.D. Analysis of nitric oxide synthase and nitrotyrosine expression in human pulmonary tuberculosis. Am. J. Respir. Crit. Care Med. 166:2002;178-186.
55. de Duve C., Wattiaux R. Functions of lysosomes. Annu. Rev. Physiol. 28:1996;435-492.
56. Bainton D. The discovery of lysosomes. J. Cell Biol. 91:1981;66S-76S.
57. Kornfeld S. Trafficking of lysosomal enzymes. FASEB J. 1:1987;462-468.
58. Mellman I., Fuchs R., Helenius A. Acidification of the endocytic and exocytic pathways. Annu. Rev. Biochem. 55:1986;663-700.
59. Ohkuma S., Poole B. Fluorescence probe measurement of the intralysosomal pH in living cells and the perturbation of pH by various agents. Proc. Natl. Acad. Sci. U. S. A. 75:1978;3327-3331.
60. Desjardins M., Hiber L.A., Parton R.G., Griffiths G. Biogenesis of phagolysosomes proceeds through a sequential series of interactions with the endocytic apparatus. J. Cell Biol. 124:1994;677-688.
61. Desjardins M. Biogenesis of phagolysosomes: the "kiss and run" hypothesis. Trends Cell Biol. 124:1995;677-688.
62. Vieira O.V., Botelho R.J., Grinstein S. Phagosome maturation: aging gracefully. Biochem. J. 366:2002;689-704.
63. Russell D.G., Mwandumba H.C., Rhoades E.E. Mycobacterium and the coat of many lipids. J. Cell Biol. 158:2002;421-426.
64. Russell D.G. Mycobacterium tuberculosis: here today, and here tomorrow. Nat. Rev., Mol. Cell Biol. 2:2001;569-577.
65. Fratti R.A., Vergne I., Chua J., Skidmore J., Deretic V. Regulators of membrane trafficking and Mycobacterium tuberculosis phagosome maturation block. Electrophoresis. 21:2000;3378-3385.
66. Deretic V., Fratti R.A. Mycobacterium tuberculosis phagosome. Mol. Microbiol. 31:1999;1603-1609.
67. Sturgill-Koszycki S., Schlesinger P.H., Chakraborty P., Haddix P.L., Collins H.L., Fok A.K., Allen D., Gluck S.L., Heuser J., Russell D.G. Lack of acidification in Mycobacterium phagosomes produced by exclusion of the vesicular proton-ATPase. Science. 263:1994;678-681.
68. Xu S., Cooper A., Sturgill-Koszycki S., van Heyningen T., Chatterjee D., Orme I., Allen P., Russell D.G. Intracellular trafficking in Mycobacterium tuberculosis and Mycobacterium avium-infected macrophages. J. Immunol. 153:1994;2568-2578.
69. Armstrong J., D'Arcy Hart P. Response of cultured macrophages to Mycobacterium tuberculosis, with observations on fusion of lysosomes with phagosomes. J. Exp. Med. 134:1971;713-740.
70. D'Arcy Hart P., Armstrong J., Brown C.A., Draper P. Ultrastructural study of the behavior of macrophages toward parasitic mycobacteria. Infect. Immun. 5:1972;803-807.
71. Sollner T.H. Vesicle tethers promoting fusion machinery assembly. Dev. Cell. 2:2002;377-378.
72. Rothman J.E. The machinery and principles of vesicle transport in the cell. Nat. Med. 8:2002;1059-1062.
73. Jahn R., Sudhof T.C. Membrane fusion and exocytosis. Annu. Rev. Biochem. 68:1999;863-911.
74. Waters M.G., Pfeffer S.R. Membrane tethering in intracellular transport. Curr. Opin. Cell Biol. 11:1999;453-459.
75. Zerial M., McBride H. Rab proteins as membrane organizers. Nat. Rev., Mol. Cell. Biol. 2:2001;107-117.
76. Via L.E., Deretic D., Ulmer R., Hibler N., Huber L., Deretic V. Arrest of mycobacterial phagosome maturation is caused by a block in vesicle fusion between stages controlled by Rab5 and Rab7. J. Biol. Chem. 272:1997;13326-13331.
77. Clemens D.L., Lee B.-Y., Horwitz M.A. Deviant expression of Rab5 on phagosomes containing the intracellular pathogens Mycobacterium tuberculosis and Legionella pneumophila is associated with altered phagosomal fate. Infect. Immun. 68:2000;2671-2684.
78. Clemens D.L., Lee B.-Y., Horwitz M.A. Mycobacterium tuberculosis and Legionella pneumophila phagosomes exhibit arrested maturation despite acquisition of Rab7. Infect. Immun. 68:2000;5154-5166.
79. Fratti R.A., Backer J.M., Gruenberg J., Corvera S., Deretic V. Role of phosphatidylinositol 3-kinase and Rab5 effectors in phagosomal biogenesis and mycobacterial phagosome maturation arrest. J. Cell Biol. 154:2001;631-644.
80. Fratti R.A., Chua J., Deretic V. Cellubrevin alterations and Mycobacterium tuberculosis phagosome maturation arrest. J. Biol. Chem. 277:2002;17320-17326.
81. Fratti R.A., Chua J., Vergne I., Deretic V. Mycobacterium tuberculosis glycosylated phosphatidylinositol causes phagosome maturation arrest. Proc. Natl. Acad. Sci. U. S. A. 100:2003;5437-5442.
82. Kusner D.J., Barton J.A. ATP stimulates human macrophages to kill intracellular virulent Mycobacterium tuberculosis via calcium-dependent phagosome-lysosome fusion. J. Immunol. 167:2001;3308-3315.
83. Malik Z.A., Iyer S.S., Kusner D.J. Mycobacterium tuberculosis phagosomes exhibit altered calmodulin-dependent signal transduction: contribution to inhibition of phagosome-lysosome fusion and intracellular survival in human macrophages. J. Immunol. 166:2001;3392-3401.
84. 2+ signaling by Mycobacterium tuberculosis is associated with reduced phagosome-lysosome fusion and increased survival within human macrophages. J. Exp. Med. 191:2000;287-302.
85. 2+ signaling and phagosome maturation in human macrophages via specific inhibition of sphingosine kinase. J. Immunol. 170:2003;2811-2815.
86. Simonsen A., Lippe R., Christoforidis S., Gaullier J.M., Brech A., Callaghan J., Toh B.H., Murphy C., Zerial M., Stenmark H. EEA1 links PI(3)K function to Rab5 regulation of endosome fusion. Nature. 394:1998;494-498.
87. Christoforidis S., McBride H.M., Burgoyne R.D., Zerial M. The Rab5 effector EEA1 is a core component of endosome docking. Nature. 397:1999;621-625.
88. McBride H.M., Rybin V., Murphy C., Giner A., Teasdale R., Zerial M. Oligomeric complexes link Rab5 effectors with NSF and drive membrane fusion via interactions between EEA1 and syntaxin 13. Cell. 98:1999;377-386.
89. Simonsen A., Gaullier J.M., D'Arrigo A., Stenmark H. The Rab5 effector EEA1 interacts directly with syntaxin-6. J. Biol. Chem. 274:1999;28857-28860.
90. Lawe D.C., Patki V., Heller-Harrison R., Lambright D., Corvera S. The FYVE domain of early endosome antigen 1 is required for both phosphatidylinositol 3-phosphate and rab5 binding. Critical role of this dual interaction for endosomal localization. J. Biol. Chem. 275:2000;3699-3705.
91. Nielsen E., Christoforidis S., Uttenweiler-Joseph S., Miaczynska M., Dewitte F., Wilm M., Hoflack B., Zerial M. Rabenosyn-5, a novel Rab5 effector, is complexed with hVPS45 and recruited to endosomes through a FYVE finger domain. J. Cell Biol. 151:2000;601-612.
92. Ferrari G., Langen H., Naito M., Pieters J.A. Coat protein on phagosomes involved in the intracellular survival of mycobacteria. Cell. 97:1999;435-447.
93. DeHostos E.L. The coronin family of actin-associated proteins. Trends Cell Biol. 9:1999;345-350.
94. Schuller S., Neefjes J., Ottenhoff T., Thole J., Young D. Coronin is involved in uptake of Mycobacterium bovis BCG in human macrophages but not in phagosome maintenance. Cell. Microbiol. 3:2001;785-793.
95. Flynn J., Chan J. Immunology of tuberculosis. Annu. Rev. Immunol. 19:2001;93-130.
96. Chan J., Fan X., Hunter S.W., Brennan P.J., Bloom B.R. Lipoarabinomannan, a possible virulence factor involved in persistence of Mycobacterium tuberculosis within macrophages. Infect. Immun. 59:1991;1755-1761.
97. Gercken J., Pryjma J., Ernst M., Flad H.D. Defective antigen presentation by Mycobacterium tuberculosis-infected monocytes. Infect. Immun. 62:1994;3472-3478.
98. Wadee A.A., Kuschke R.H., Dooms T.G. The inhibitory effects of Mycobacterium tuberculosis on MHC class II expression by monocytes activated with riminophenazines and phagocyte stimulants. Clin. Exp. Immunol. 100:1995;434-439.
99. Hmama Z., Gabathuler R., Jefferies W.A., Dejong G., Reiner N.E. Attenuation of HLA-DR expression by mononuclear phagocytes infected with Mycobacterium tuberculosis is related to intracellular sequestration of immature Class II heterodimers. J. Immunol. 161:1998;4882-4893.
100. Wojciechowski W., Desanctis J., Skamene E., Radzioch D. Attenuation of MHC Class II expression in macrophages infected with Mycobacterium bovis bacillus Calmette-Guerin involves class II transactivator and depends on Nramp1 gene. J. Immunol. 163:1999;2688-2696.
101. Noss E.H., Tai R.K., Sellati T.J., Radolf J.D., Belisle J., Golenbock D.T., Boom W.H., Harding C.V. Toll-like receptor 2-dependent inhibition of macrophage class II MHC expression and antigen processing by 19-kDa lipoprotein of Mycobacterium tuberculosis. J. Immunol. 167:2001;910-918.
102. Ramachandra L., Noss E., Boom W.H., Harding C.V. Processing of Mycobacterium tuberculosis antigen 85B involves intraphagosomal formation of peptide-major histocompatibility complex II complexes and is inhibited by live bacilli that decrease phagosome maturation. J. Exp. Med. 194:2001;1421-1432.
103. Pancholi P., Mirza A., Bhardwaj N., Steinman R.M. Sequestration from immune CD4+ T cells of mycobacteria growing in human macrophages. Science. 260:1993;984-986.
104. Brightbill H.D., Libraty D.H., Krutzik S.R., Yang R.B., Belisle J.T., Bleharski J.R., Maitland M., Norgard M.V., Plevy S.E., Smale S.T., Brennan P.J., Bloom B.R., Godowski P.J., Modlin R.L. Host defense mechanisms triggered by microbial lipoproteins through toll-like receptors. Science. 285:1999;732-736.
105. Thoma-Uszynski S., Stenger S., Takeuchi O., Ochoa M.T., Engele M., Sieling P.A., Barnes P.F., Rollinghoff M., Bolcskei P.L., Wagner M., Akira S., Norgard M.V., Belisle J.T., Godowski P.J., Bloom B.R., Modlin R.L. Induction of direct antimicrobial activity through mammalian Toll-like receptors. Science. 291:2001;1544-1547.
106. Underhill D.M., Ozinsky A., Hajjar A.M., Stevens A., Wilson C.B., Bassetti M., Aderem A. The Toll-like receptor 2 is recruited to macrophage phagosomes and discriminates between pathogens. Nature. 401:1999;811-815.
107. Ting L.-M., Kim A.C., Cattamanchi A., Ernst J.D. Mycobacterium tuberculosis inhibits IFN-g transcriptional responses without inhibiting activation of STAT1. J. Immunol. 163:1999;3898-3906.
108. Flynn J.L., Goldstein M.M., Chan J., Triebold K.J., Pfeffer K., Lowenstein C.J., Schreiber R., Mak T.W., Bloom B.R. Tumor necrosis factor is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity. 2:1995;561-572.
109. Adams L.B., Mason C.M., Kolls J.K., Scollard D., Krahenbuhl J.L., Nelson S. Exacerbation of acute and chronic murine tuberculosis by administration of a tumor necrosis factor receptor-expressing adenovirus. J. Infect. Dis. 171:1995;400-405.
110. Bean A.G., Roach D.R., Briscoe H., France M.P., Korner H., Sedgwick J.D., Britton W.J. Structural deficiencies in granuloma formation in TNF gene-targeted mice underlie the heightened susceptibility to aerosol Mycobacterium tuberculosis infection, which is not compensated for by lymphotoxin. J. Immunol. 162:1999;3504-3511.
111. Scanga C.A., Mohan V.P., Yu K., Joseph H., Tanaka K.E., Chan J., Flynn J. Reactivation of latent tuberculosis: variations on the Cornell murine model. Infect. Immun. 67:1999;4531-4538.
112. Mohan V.P., Scanga C.A., Yu K., Scott H.M., Tanaka K.E., Tsang E., Tsai M.C., Flynn J.L., Chan J. Tumor necrosis factor-α is required to prevent reactivation and limit pathology in latent murine tuberculosis. Infect. Immun. 69:2001;1847-1855.
113. Roach R.R., Bean A.G.D., Demangel C., France M.P., Briscoe H., Britton W.J. TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J. Immunol. 168:2002;4620-4627.
114. Sedgwick J.D., Riminton D.S., Cyster J.G., Korner H. Tumor necrosis factor: a master regulator of leukocyte movement. Immunol. Today. 21:2000;110-113.
115. Rook G.A.W., Taverne J., Leveton C., Steele J. The role of gamma-interferon, vitamin D3 metabolites and tumor necrosis factor in the pathogenesis of tuberculosis. Immunology. 62:1987;229-234.
116. Rook G.A.W. Mycobacteria, cytokines and antibiotics. Pathol. Biol. 38:1990;276-280.
117. Moreira A.L., Tsenova-Berkova L., Wang J., Laochumroonvorapong P., Freeman S., Kaplan G. Effect of cytokine modulation by thalidomide on the granulmatous response in murine tuberculosis. Tuber. Lung Dis. 78:1997;47-55.
118. Bekker L.-G., Moreira A.L., Bergtold A., Freeman S., Bernard R., Kaplan G. Immunopathologic effects of tumor necrosis factor alpha in murine mycobacterial infection are dose dependent. Infect. Immun. 68:2000;6954-6961.
119. Tramontana J.M., Utaipat U., Molloy A., Akarasewi P., Burroughs M., Makonkawkeyoon S., Johnson B., Klausner J.D., Rom W., Kaplan G. Thalidomide treatment reduces tumor necrosis factor alpha production and enhances weight gain in patients with pulmonary tuberculosis. Mol. Med. 1:1995;384-397.
120. Smith S., Liggitt D., Jeromsky E., Tan X., Skerrett S.J., Wilson C.B. Local role for tumor necrosis factor alpha in the pulmonary inflammatory response to Mycobacterium tuberculosis infection. Infect. Immun. 70:2002;2082-2089.
121. Shanahan J.C., St. Clair E.W. Tumor necrosis factor-α blockade: a novel therapy for rheumatic disease. Clin. Immunol. 103:2002;231-242.
122. Lugering A., Schmidt M., Lugering N., Pauels H.-G., Domschke W., Kucharzik T. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroentrology. 121:2001;1145-1157.
123. ten Hove T., van Montfrans C., Peppelenbosch M.P., van Deventer S.J.H. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut. 50:2002;206-211.
124. Agnholt J., Kaltoft K. Infliximab downregulates interferon-g production in activated gut T-lymphocytes from patients with Crohn's disease. Cytokine. 15:2001;212-222.
125. Keane J., Gershon S., Wise R.P., Mirabile-Levens E., Kasznica J., Schwieterman W.D., Siegel J.N., Braun M.M. Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. N. Engl. J. Med. 345:2001;1098-1104.
126. Keane J., Gershon S.K. Tuberculosis and treatment with infliximab. N. Engl. J. Med. 346:2002;625-626.
127. Flynn J., Chan J. Tuberculosis: latency and reactivation. Infect. Immun. 69:2001;4195-4201.
128. Capuano S.V. III, Croix D.A., Pawar S., Zinovik A., Myers A., Lin P.L., Bissel S., Fuhrman C., Klein E., Flynn J.L. Experimental Mycobacterium tuberculosis infection of cynomolgus macaques closely resembles the various manifestations of human M. tuberculosis infection. Infect. Immun. 71:2003;5831-5844.